SpeeDx has submitted its Plex PCR RespiVirus test for approval to Australia’s Therapeutic Goods Administration (TGA).
The SpeeDx Plex PCR RespiVirus test detects major respiratory pathogens including Influenza A, Influenza B, Rhinoviruses (A & B), Respiratory Syncytial Viruses (A & B), Human metapneumovirus, Adenoviruses, and Human parainfluenza viruses 1, 2, 3 and 4.
The impact of these respiratory pathogens is seen most heavily during late winter-early spring, with combined health and economic impacts attributed to absenteeism, hospitalization, and serious complications leading to admission in intensive care, and in some instances death.
“We are excited to expand our infectious disease portfolio into the respiratory market,” said Colin Denver, SpeeDx CEO. “SpeeDx patented technology enables multiple targets to be easily combined into a single test, which means laboratories can get results for more patients over the course of a work day compared to standard technologies. This is particularly important during the peak respiratory-testing seasons when laboratories are resource challenged.”
